The profibrotic role of endothelin-1: Is the door still open for the treatment of fibrotic diseases?
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
The endothelin (ET) system consists of two G-protein-coupled receptors (ETA and ETB), three peptide ligands (ET-1, ET-2 and ET-3), and two activating peptidases (endothelin-converting enzyme-, ECE-1 and ECE-2). While initially described as a vasoregulatory factor, shown to influence several cardiovascular diseases, from hypertension to heart failure, ET-1, the predominant form in most cells and tissues, has expanded its pathophysiological relevance by recent evidences implicating this factor in the regulation of fibrosis. In this article, we review the current knowledge of the role of ET-1 in the development of fibrosis, with particular focus on the regulation of its biosynthesis and the molecular mechanisms involved in its profibrotic actions. We summarize also the contribution of ET-1 to fibrotic disorders in several organs and tissues. The development and availability of specific ET receptor antagonists have greatly stimulated a number of clinical trials in these pathologies that unfortunately have so far given negative or inconclusive results. This review finally discusses the circumstances underlying these disappointing results, as well as provides basic and clinical researchers with arguments to keep exploring the complex physiology of ET-1 and its therapeutic potential in the process of fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495
BUILD-3: A Randomized, Controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis
King, T. E., Brown, K. K., Raghu, G., du Bois, R. M., Lynch, D. A., Martinez, F., Valeyre, D., Leconte, I., Morganti, A., Roux, S., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201011-1874oc · Cited by 718 · cited 1×
“However, no significant difference between treatment groups was observed in the time to disease worsening (the primary end-point) (King et al., 2011).”
BackgroundRole of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders
Piera-Velazquez, S., Li, Z., & Jimenez, S. A. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.06.001 · Cited by 580
Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan: A Parallel, Randomized Trial
Raghu, G., Behr, J., Brown, K. K., Egan, J. J., Kawut, S. M., Flaherty, K. R., Martinez, F. J., Nathan, S. D., Wells, A. U., Collard, H. R., et al. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-9-201305070-00003 · Cited by 553
BUILD-1: A Randomized Placebo-controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis
King, T. E., Behr, J., Brown, K. K., du Bois, R. M., Lancaster, L., de Andrade, J. A., Stähler, G., Leconte, I., Roux, S., & Raghu, G. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200705-732oc · Cited by 500
Amiri, F., Virdis, A., Neves, M. F., Iglarz, M., Seidah, N. G., Touyz, R. M., Reudelhuber, T. L., & Schiffrin, E. L. (2004) · Circulation · doi:10.1161/01.cir.0000144462.08345.b9 · Cited by 346 · cited 2×
“…modified to overexpress ET-1 in the endothelium show enhanced ECMdeposition, resulting in structural remodeling of small arteries, an action that occurswithout elevation of blood pressure, but can be greatly potentiated by salt loading-induced hypertension (Amiri et al., 2010; Amiri et al., 2004).”
BackgroundMolecular Regulation of the Endothelin-1 Gene by Hypoxia
Yamashita, K., Discher, D. J., Hu, J., Bishopric, N. H., & Webster, K. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m011344200 · Cited by 340 · cited 2×
“In fact, as extensively reported in endothelial cells, AP-1 transcription factor plays a central role in the control of constitutive and regulated transcription of the ET-1 gene, coordinating transcriptional responses to GATA-2, HIF-1 and Smad transcription factors (Kawana et al., 1995; RodriguezPascual et al., 2004;…”
BackgroundGenetic diseases of connective tissues: cellular and extracellular effects of ECM mutations
Bateman, J. F., Boot-Handford, R. P., & Lamandé, S. R. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2520 · Cited by 338
Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial
Raghu, G., Million-Rousseau, R., Morganti, A., Perchenet, L., Behr, J., & the MUSIC Study Group (2013) · European Respiratory Journal · doi:10.1183/09031936.00104612 · Cited by 277 · cited 2×
“…with macitentan, a dual blocker developed from the structure of bosentan and showing increased safety and efficacy in preclinical studies, has also yielded negative results in patients with IPF or SSc (MUSIC: Macitentan USe in an Idiopathic pulmonary fibrosis Clinical study) (Raghu et al., 2013b).”
BackgroundResultFibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1
Shi-wen, X., Denton, C. P., Holmes, A. M., Black, C. M., Abraham, D. J., Dashwood, M. R., Bou-Gharios, G., & Pearson, J. D. (2001) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2001.01256.x · Cited by 243 · cited 3×
“…types involved in the fibrotic process, including lung, skin or cardiacfibroblasts or hepatic stellate cells, among others, have been described to generate significant amounts of bioactive ET-1 (Abraham et al., 1997; Katwa, 2003; Rockey et al., 1998; Shi-Wen et al., 2004; Shi-Wen et al., 2001).”
Background
Cited by
Cardiac Fibrosis: The Fibroblast Awakens
Travers, J. G., Kamal, F. A., Robbins, J., Yutzey, K. E., & Blaxall, B. C. (2016) · Circulation Research · doi:10.1161/circresaha.115.306565 · Cited by 1,596
Cardiac fibrosis in myocardial infarction—from repair and remodeling to regeneration
Talman, V., & Ruskoaho, H. (2016) · Cell and Tissue Research · doi:10.1007/s00441-016-2431-9 · Cited by 905
Pathophysiology of systemic sclerosis: current understanding and new insights
Cutolo, M., Soldano, S., & Smith, V. (2019) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2019.1614915 · Cited by 369
Getting to the Heart of the Matter: New Insights Into Cardiac Fibrosis
Leask, A. (2015) · Circulation Research · doi:10.1161/circresaha.116.305381 · Cited by 340
Novel therapeutic strategies targeting fibroblasts and fibrosis in heart disease
Gourdie, R. G., Dimmeler, S., & Kohl, P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.89 · Cited by 332
Metadata
- Authors
- Rodríguez-Pascual, F., Busnadiego, O., & González-Santamaría, J.
- Venue
- Life Sciences
- Publisher
- Elsevier BV
- Published
- 2014-11
- Volume
- 118
- Issue
- 2
- Pages
- 156-164
- ISSN
- 0024-3205 (ISSN-L)
- OpenAlex
- W1964896698
- Cited by
- 83
- References
- 13
- FWCI
- 5.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The profibrotic role of endothelin-1: Is the door still open for the treatment of fibrotic diseases? https://app.cochat.ai/papers/10.1016/j.lfs.2013.12.024
- The paper
- Rodríguez-Pascual, F., Busnadiego, O., & González-Santamaría, J. (2014). The profibrotic role of endothelin-1: Is the door still open for the treatment of fibrotic diseases? Life Sciences. https://doi.org/10.1016/j.lfs.2013.12.024
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.